Navigation Links
MINRAD International, Inc. Announces Change in Distribution Agreement with RxElite Holdings, Inc.
Date:9/11/2008

ORCHARD PARK, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced that it has notified RxElite Holdings, Inc., a wholly-owned subsidiary of RxElite Inc. (OTC Bulletin Board: RXEI), that it is transitioning its relationship with respect to RxElite Holdings, Inc.'s rights to be the exclusive distributor of certain Minrad International Inc.'s anesthetic products in the United States. Minrad has decided to move into a non-exclusive distributor arrangement with RxElite.

"As we discussed in our second quarter conference call on August 14, 2008, we have had ongoing dialogue with the senior management of RxElite to assess and determine how to increase our joint penetration of anesthetic products in the United States market. We believe this action will maximize the expertise of sales forces of both companies as well as the in-house support capabilities which RxElite has built to launch sevoflurane in the U.S. human anesthetic market," said David DiGiacinto, President and Chief Operating Officer.

Kirk Kamsler, Minrad's Senior Vice President, Commercial Development also commented, "We expect and will work towards ensuring that this ongoing change in selling strategy for our present and future anesthetics in the U.S. market will be transparent to both the distribution customers and end users of this product. Minrad already launched in June a direct selling effort for sevoflurane and isoflurane into the U.S. veterinary market."

Contact: David DiGiacinto, President & Chief Operating Officer

ddigiacinto@minrad.com

Kirk Kamsler, Senior Vice President, Commercial Development

kkamsler@minrad.com

Charles R. Trego, Jr., Executive Vice President & Chief

Financial Officer

ctrego@minrad.com

(716) 855-1068

http://www.minrad.com

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB/A, filed with the Securities and Exchange Commission on April 21, 2008. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
2. MINRAD International, Inc. Announces the Start of the MINRAD International Distributor Meeting in Cape Town, South Africa
3. MINRAD International, Inc. to Discuss 2007 Fourth Quarter and Full Year Financial Results on Monday, March 31, 2008
4. MINRAD International, Inc. Announces 2007 Financial Results
5. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
6. MINRAD International, Inc. to Discuss 2008 Second Quarter Financial Results on Thursday, August 14, 2008
7. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
8. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
9. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
10. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
11. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: